The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Patients With Hematologic Cancers at Increased Risk for Adverse COVID-19 Outcomes
December 6th 2020December 6, 2020 — Patients with hematologic malignancies are at increased risk for significant morbidity and mortality from coronavirus disease 2019, and the risk of death appeared to be greatest in those who were older, had more severe infection, a poorer prognosis, or who decided to forego intensive treatment
DREAMM-6 Data Set the Stage for Further Study of Belantamab Mafodotin–Based Triplet in Myeloma
December 6th 2020December 5, 2020 - The addition of belantamab mafodotin to bortezomib and dexamethasone elicited high response rates and a suitable safety profile in patients with relapsed or refractory multiple myeloma.
Cilta-Cel Confers 97% ORR in Relapsed/Refractory Multiple Myeloma
December 6th 2020December 5, 2020 - Treatment with the CAR T-cell therapy ciltacabtagene autoleucel led to a high response rate and an acceptable safety profile at the recommended phase 2 dose in patients with relapsed or refractory multiple myeloma.
Novel CAR Engineering Overcomes Resistance in Large B-Cell Lymphoma With CD58 Loss
December 5th 2020December 5, 2020 - Engineering chimeric antigen receptors T cells to overcome CD58 loss may provide a path forward for patients with large B-cell lymphomas who do not respond to treatment with immunotherapy.
Anti-ICOS Antibody MEDI-570 Elicits Durable Responses in Relapsed/Refractory T-cell Lymphomas
December 5th 2020The anti-inducible T-cell co-stimulator monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma.
First-in-Human Trial Demonstrates Clinical Activity With ROR1-Directed ADC in MCL and DLBCL
December 5th 2020December 5, 2020 - VLS-101, a novel ROR1-targeted antibody-drug conjugate, demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable safety profile in patients with heavily pretreated mantle cell lymphoma and diffuse large B-cell lymphoma.
Highly Refractory Myeloma Has Deep and Durable Responses With Ide-cel
December 5th 2020December 5, 2020 - Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor T-cell therapy idecabtagene vicleucel in updated findings presented from the phase 1 CRB-401 trial.
Survival Benefit of Venetoclax and Rituximab in Relapsed/Refractory CLL Persists Out to Five Years
December 5th 2020December 5, 2020 - Patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax and rituximab had a sustained progression-free survival and overall survival benefit at five years compared with those treated with bendamustine and rituximab.
Weekly Selinexor Regimen Shows Significant Benefit in Pretreated Multiple Myeloma
December 5th 2020December 5, 2020 - A subgroup analysis from the phase 3 BOSTON study demonstrated that once weekly selinexor, bortezomib, and dexamethasone was superior to bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma who had received 1 to 3 prior therapies.
Racial and Ethnic Related Socioeconomic Disparities Influence Survival Outcomes in AML
December 5th 2020December 5, 2020 - Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area.
Navitoclax/Ruxolitinib Combo Improves Spleen Volume, Symptoms in Relapsed/Refractory Myelofibrosis
December 5th 2020December 5, 2020 - The addition of navitoclax to ruxolitinib resulted in a clinically meaningful improvement in spleen volume and total symptom score in patients with myelofibrosis who no longer benefited from prior ruxolitinib therapy.
Ruxolitinib Demonstrates Superior Efficacy Over Best Available Therapy in Chronic GVHD
December 5th 2020December 5, 2020 - Ruxolitinib was found to elicit a significantly higher overall response rate, a substantially greater improvement in failure-free survival, and greater symptom improvement versus best available therapy in patients with chronic graft-versus-host disease with an inadequate response to corticosteroids.
Oxidative Stress, Antioxidant Status Remain High in Nigerian Patients With Prostate Cancer
December 4th 2020Nigerian patients with prostate cancer are noted as having higher levels of total plasma peroxide, malondialdehyde, and nitric oxide, as well as lower levels of total antioxidant capacity, even while undergoing androgen-deprivation therapy compared with Nigerian men who don't have prostate cancer.
Next-Generation CD47 Blocker ALX148/Azacitidine Combo Under Exploration in MDS
December 4th 2020December 4, 2020 - The first patient with higher-risk myelodysplastic syndrome has been dosed with a novel combination comprised of the next-generation CD47 blocker ALX148 plus azacitidine as part of the phase 1/2 ASPEN-02 study, the first of several planned studies to examine the agent in those with myeloid malignancies.
Adjuvant Nivolumab Displays Survival Benefits in High-Risk Resected Melanoma
December 4th 2020December 4, 2020 — Adjuvant nivolumab demonstrated clinically meaningful improvements in relapse-free survival, overall survival, and distant metastasis-free survival vs placebo in patients with high-risk resected melanoma, even after accounting for disease stage and post-recurrence survival, supporting the use of the anti–PD-1 antibody as a standard adjuvant therapy.
Novel Approaches Challenge Toxicity Restraints in Classical Hodgkin Lymphoma
December 4th 2020The ability to increase the efficacy and decrease the toxicity of treatment regimens in classical Hodgkin lymphoma had stood at odds until the introduction of response-adapted treatment approaches, antibody-drug conjugates, and checkpoint inhibitors to the paradigm.